罗格列酮对2型糖尿病患者血浆C反应蛋白和纤溶酶原激活剂抑制剂(PAI1)活性的影响

Effect of rosiglitazone on plasma activity of CRP and PAI1 in type 2 diabetes mellitus.

目的运用胰岛素增敏剂罗格列酮治疗2型糖尿病患者,观察罗格列酮对2型糖尿病患者血浆C反应蛋白(CRP)和纤溶酶原激活剂抑制剂(PAI1)活性水平的影响。方法50例2型糖尿病患者,口服罗格列酮(文迪雅)4mg/d,共12w,观察治疗前后的血浆CRP和PAI1活性、血糖、血脂、胰岛素水平,计算胰岛素敏感指数和胰岛素抵抗指数,并将各指标进行分析比较。结果罗格列酮治疗后2型糖尿病患者血浆CRP及PAI1活性降低(P<0.05,P<0.01),血糖、血脂、胰岛素水平及胰岛素抵抗指数降低(P均<0.05);胰岛素敏感指数明显升高(P<0.05)。结论罗格列酮在降低血糖、改善胰岛素抵抗、提高胰岛素敏感指数的同时,能降低血浆CRP水平,增强糖尿病患者纤溶系统的活性,对心血管起到保护作用。

Objective To investigate the effect of insulinsensitizer （Rosiglitazone） on type 2 diabetes mellitus. Study the influence of Rosiglitazone on the plasma activity of CRP and PAI1 in type 2 diabetes mellitus. Methods 50 patients with type 2 diabetes mellitus received orally Rosiglitazonc 4mg/d for 12 weeks. To observe the level of plasma activity of CRP and PAI1 in type 2 diabetes mellitus before and after treatment with Rosiglitazone. Blood glucose and insulin were ruensurated before and after treatment. Calculated the insulin resistance index and insulin sensitive index. Analysed the results. Results After the treatment with Rosiglitazone, the plasma activity of CRP and PAI1 was decreased significantly. （ P 〈 0.05, P 〈 0.01 ） ; Blood glucose and insulin was decreased significantly after treatment（ P 〈 0.05, P 〈 0.05 ） ,The insulin resistance index decreased and insulin sensitive index increased significantly（ P 〈 0.05, P 〈 0.05 ）. Conclusion Rosiglitazone can lower level of blood glucose , insulin and CRP,improve insulin sensitivity, decrease insulin resistance . Rosiglitazone can enhancement the activity of fibrinolytic system. It play a role of protection in cardiovascular system.